(Q83376683)
Statements
Randomized, double-blind, placebo-controlled, single intravenous dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of the novel coronary smooth muscle cell proliferation inhibitor Biolimus A9 in healthy individuals (English)
Wolfgang Steudel
Colleen Dingmann
Yan-Ling Zhang
Jamie Bendrick-Peart
Claudia Clavijo
John Shulze
Ronald Betts